📗 Cite This Artifact
NPRL2 Gene
NPRL2 Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NPRL2 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>NPRL2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NPR2-Like (GATOR1 Complex Subunit)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>3p21.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10316</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000131653</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q8WX92</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">GATOR1</td>
<td>Rag GAP activity</td>
</tr>
<tr>
<td class="label">GATOR2</td>
<td>Positive regulator</td>
</tr>
<tr>
<td class="label">Sestrin1/2</td>
<td>Leucine sensing</td>
</tr>
<tr>
<td class="label">CASTOR1/2</td>
<td>Arginine sensing</td>
</tr>
<tr>
<td class="label">SAMTOR</td>
<td>Methionine sensing</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">DEPDC5</td>
<td>GATOR1 subunit</td>
</tr>
<tr>
<td class="label">TSC1/2</td>
<td>Parallel mTOR regulation</td>
</tr>
<tr>
<td class="label">FLCN</td>
<td>mTOR regulation</td>
</tr>
<tr>
<td class="label">PTEN</td>
<td>PI3K-mTOR pathway</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Sirolimus (Ra
NPRL2 Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NPRL2 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>NPRL2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NPR2-Like (GATOR1 Complex Subunit)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>3p21.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10316</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000131653</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q8WX92</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">GATOR1</td>
<td>Rag GAP activity</td>
</tr>
<tr>
<td class="label">GATOR2</td>
<td>Positive regulator</td>
</tr>
<tr>
<td class="label">Sestrin1/2</td>
<td>Leucine sensing</td>
</tr>
<tr>
<td class="label">CASTOR1/2</td>
<td>Arginine sensing</td>
</tr>
<tr>
<td class="label">SAMTOR</td>
<td>Methionine sensing</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">DEPDC5</td>
<td>GATOR1 subunit</td>
</tr>
<tr>
<td class="label">TSC1/2</td>
<td>Parallel mTOR regulation</td>
</tr>
<tr>
<td class="label">FLCN</td>
<td>mTOR regulation</td>
</tr>
<tr>
<td class="label">PTEN</td>
<td>PI3K-mTOR pathway</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Sirolimus (Rapamycin)</td>
<td>Allosteric mTORC1 inhibitor</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>Rapamycin analog</td>
</tr>
<tr>
<td class="label">Torin1</td>
<td>Catalytic mTOR inhibitor</td>
</tr>
<tr>
<td class="label">Subunit</td>
<td>Function</td>
</tr>
<tr>
<td class="label">NPRL2</td>
<td>Catalytic GAP activity</td>
</tr>
<tr>
<td class="label">NPRL3</td>
<td>Structural scaffold</td>
</tr>
<tr>
<td class="label">DEPDC5</td>
<td>Regulatory subunit</td>
</tr>
<tr>
<td class="label">Autophagy Stage</td>
<td>NPRL2 Effect</td>
</tr>
<tr>
<td class="label">Initiation</td>
<td>ULK1 complex activation</td>
</tr>
<tr>
<td class="label">Nucleation</td>
<td>PI3K-III complex recruitment</td>
</tr>
<tr>
<td class="label">Elongation</td>
<td>LC3 lipidation</td>
</tr>
<tr>
<td class="label">Fusion</td>
<td>Autophagosome-lysosome fusion</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>NPRL2 Expression</td>
</tr>
<tr>
<td class="label">Pyramidal neurons</td>
<td>High</td>
</tr>
<tr>
<td class="label">Interneurons</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Seizure type</td>
<td>Focal seizures, often with auditory features</td>
</tr>
<tr>
<td class="label">Onset</td>
<td>Childhood to adolescence</td>
</tr>
<tr>
<td class="label">Penetrance</td>
<td>Incomplete (60-70%)</td>
</tr>
<tr>
<td class="label">EEG findings</td>
<td>Temporal/focal epileptiform discharges</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTORC1</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>mTORC1</td>
</tr>
<tr>
<td class="label">Torin1</td>
<td>mTORC1/mTORC2</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">AMPK</td>
<td>Energy sensing</td>
</tr>
<tr>
<td class="label">ULK1</td>
<td>Autophagy initiation</td>
</tr>
<tr>
<td class="label">TFEB</td>
<td>Lysosomal biogenesis</td>
</tr>
<tr>
<td class="label">Wnt</td>
<td>Developmental signaling</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Use</td>
</tr>
<tr>
<td class="label">Yeast</td>
<td>Basic mechanisms</td>
</tr>
<tr>
<td class="label">Drosophila</td>
<td>Development</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>Development, screening</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>In vivo models</td>
</tr>
<tr>
<td class="label">iPSC neurons</td>
<td>Disease modeling</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Strategy</td>
</tr>
<tr>
<td class="label">mTORC1</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">GATOR1</td>
<td>Stabilization</td>
</tr>
<tr>
<td class="label">Autophagy</td>
<td>Induction</td>
</tr>
<tr>
<td class="label">Metabotropic</td>
<td>Ketogenic diet</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">20 edges</a></td>
</tr>
</table>
Nprl2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The NPRL2 gene (NPR2-Like, GATOR1 Complex Subunit) encodes a core component of the GATOR1 complex, which negatively regulates mTORC1 signaling in response to amino acid availability. NPRL2 is a tumor suppressor and mutations cause familial epilepsy. Dysregulated [mTOR](/entities/mtor) signaling is a hallmark of many neurodegenerative diseases. [@gator]
Gene Information
Protein Structure
NPRL2 is a 380-amino acid protein with:
- GAP activity towards Rag GTPases
- Protein-protein interaction domains
- Multiple phosphorylation sites
Molecular Function
NPRL2 is essential for mTORC1 inhibition:
Expression Pattern
NPRL2 is ubiquitously expressed:
- High in brain, heart, kidney
- Moderate in liver, lung
- Low in other tissues
In the brain:
- [Neurons](/entities/neurons) in [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus)
- Cerebellar Purkinje cells
- Glial cells
Disease Associations
Focal Epilepsy
- Autosomal dominant focal epilepsy (FLE)
- Mutations cause epilepsy without brain lesions
- Incomplete penetrance
- PMID: 23471845(https://pubmed.ncbi.nlm.nih.gov/23471845/), PMID: 23695510(https://pubmed.ncbi.nlm.nih.gov/23695510/)
Alzheimer's Disease
- mTORC1 hyperactivation in AD
- Impaired autophagy leads to protein aggregation
- Synaptic plasticity deficits
- PMID: 25396082(https://pubmed.ncbi.nlm.nih.gov/25396082/), PMID: 26255403(https://pubmed.ncbi.nlm.nih.gov/26255403/)
Parkinson's Disease
- Dysregulated [mTOR](/mechanisms/mtor-signaling-pathway) signaling
- [Autophagy](/entities/autophagy) defects in PD
- [Alpha-synuclein](/proteins/alpha-synuclein) accumulation
- PMID: 26925799(https://pubmed.ncbi.nlm.nih.gov/26925799/), PMID: 28749530(https://pubmed.ncbi.nlm.nih.gov/28749530/)
Tuberous Sclerosis
- Related to TSC1/TSC2 pathway
- mTOR hyperactivation
- Seizures and developmental issues
Cancer
- Tumor suppressor
- Loss in various cancers
- Renal cell carcinoma
Therapeutic Implications
- mTOR Inhibitors: Rapamycin, everolimus
- Autophagy Inducers: Trehalose, resveratrol
- Ketogenic Diet: Bypasses mTOR dysregulation
- Gene Therapy: For epilepsy
Animal Models
- Nprl2 knockout mice: Embryonic lethal
- Conditional knockouts: Seizures, autism-like behaviors
- Zebrafish: Developmental defects
Background
The study of Nprl2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [DEPDC5 Gene complex subunit - GATOR1](/genes/depdc5)
- GATOR Complex - Amino acid sensing
- [mTOR Pathway - Growth regulation](/entities/mtor)
- [Autophagy](/entities/autophagy)-Lysosomal Pathway - Protein clearance
- [Epilepsy - Primary disease](/diseases/epilepsy)
- [Alzheimer's Disease](/diseases/alzheimers-disease) - Disease association
External Links
- [NCBI Gene NPRL2](https://www.ncbi.nlm.nih.gov/gene/10316)
- [UniProt Q8WX92](https://www.uniprot.org/uniprotkb/Q8WX92)
- [HGNC NPRL2](https://www.genenames.org/data/hgnc_data.php?hgnc_id=8004)
- [Ensembl NPRL2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131653)
Molecular Mechanisms
GATOR1 Complex Assembly and Function
The GATOR1 complex represents the primary amino acid sensing machinery that negatively regulates mTORC1 signaling[gator]. NPRL2 serves as the central scaffold that coordinates complex assembly:
The complete complex has a molecular weight of approximately 350 kDa and localizes primarily to the cytosol, with enrichment at the lysosomal surface where mTORC1 activation occurs.
Rag GTPase Regulation
NPRL2 directly catalyzes GTP hydrolysis on Rag GTPases, a critical regulatory step:
- Rag GTPase structure: Heterodimers of RagA/B (or Rag1/2) with RagC/D (or Rag3/4)
- Active state: RagA/B-GTP recruits mTORC1 to the lysosomal surface
- Inactive state: GDP-bound Rags prevent mTORC1 recruitment
- NPRL2 GAP activity: Accelerates GTP hydrolysis on RagA/B by ~10,000-fold
- Substrate specificity: Prefers RagA over RagB; exhibits some specificity for RagC
Amino Acid Sensing Pathway
The GATOR1 complex functions within a larger amino acid sensing network:
Integration with Cellular Metabolic Status
NPRL2 function intersects with multiple metabolic pathways:
- AMPK signaling: Energy depletion activates AMPK, which phosphorylates and inhibits mTORC1 through TSC1/2
- Growth factor signaling: PI3K-Akt pathway modulates mTORC1 activity independently of amino acids
- Stress responses: p53 and hypoxia-inducible factor pathways affect GATOR1 function
Neurological Disease Mechanisms
Alzheimer's Disease Pathogenesis
In Alzheimer's disease, NPRL2 dysfunction contributes to several key pathological features:
- mTORC1 hyperactivation: Reduced GATOR1 activity permits uncontrolled mTORC1 signaling
- Autophagy impairment: Active mTORC1 inhibits autophagy initiation, blocking clearance of Aβ and tau
- Synaptic dysfunction: mTOR-regulated local protein synthesis at synapses becomes dysregulated
- Protein synthesis dysregulation: Aberrant phosphorylation of 4E-BP and S6K affects synaptic plasticity
Parkinson's Disease Mechanisms
NPRL2 alterations in PD involve:
- mTOR pathway dysregulation: Altered mTOR signaling in dopaminergic neurons
- Autophagy defects: Impaired autophagic clearance of alpha-synuclein aggregates
- Lysosomal dysfunction: Connection to GBA and other lysosomal genes mutated in PD
- Neuronal vulnerability: Enhanced susceptibility of substantia nigra neurons
Epilepsy Pathophysiology
NPRL2 mutations cause focal epilepsy through[nprl]:
Interaction with Other Neurodegeneration Genes
NPRL2 interacts with multiple genes implicated in neurodegeneration:
Therapeutic Strategies
mTOR Inhibitors in Clinical Practice
Autophagy-Inducing Strategies
Beyond mTOR inhibition, alternative autophagy enhancement approaches:
- Trehalose: mTOR-independent autophagy inducer
- Resveratrol: SIRT1-dependent autophagy activation
- Lithium: IMPase inhibition, inositol depletion
- Carbamazepine: TFEB activation
Gene Therapy Approaches
For NPRL2-related epilepsy:
- AAV-mediated delivery: Brain-targeted vector systems
- CRISPR-based correction: Allele-specific editing
- Antisense oligonucleotides: Variant-specific targeting
Ketogenic Diet Therapy
Metabolic therapy offers an alternative approach:
- Mechanism: Reduces glycolysis, increases ketone utilization
- Effect on mTOR: Decreases mTORC1 signaling through AMPK activation
- Benefits: Seizure reduction, improved cognition
- Considerations: Dietary compliance, lipid profile
Research Models and Methods
Cellular Models
- Neuronal cultures: Primary cortical and hippocampal neurons
- iPSC-derived neurons: Patient-specific disease modeling
- Organotypic slices: Preserved brain architecture
Animal Models
- Nprl2 knockout mice: Embryonic lethal (E7.5-9.5)
- Conditional knockouts: Brain-specific deletion for survival
- heterozygous mice: Show behavioral abnormalities
Experimental Approaches
- CRISPR/Cas9: Gene editing for mutation modeling
- Proteomics: GATOR1 complex composition analysis
- Metabolomics: Metabolic pathway profiling
- Single-cell RNAseq: Cell type-specific expression
Biomarkers and Diagnostics
Genetic Testing
- Panel testing: Epilepsy gene panels including NPRL2
- Whole exome sequencing: Comprehensive variant detection
- Family screening: Cascade testing for relatives
Functional Assays
- Fibroblast studies: mTORC1 hyperactivation assessment
- Protein expression: Western blot for NPRL2 levels
- Enzyme activity: Rag GAP activity measurement
Summary
NPRL2 (NPR2-Like, GATOR1 Complex Subunit) encodes a core component of the GATOR1 complex, the primary negative regulator of mTORC1 signaling in response to amino acid availability. Through its catalytic GAP activity toward Rag GTPases, NPRL2 plays essential roles in nutrient sensing, autophagy regulation, protein synthesis control, and cellular growth decisions. Mutations in NPRL2 cause autosomal dominant focal epilepsy, while dysregulated mTORC1 signaling contributes to Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Understanding NPRL2 function provides insights into the pathogenesis of these conditions and identifies therapeutic targets for intervention.
Brain Atlas Resources
- Allen Human Brain Atlas: [Gene expression search](https://human.brain-map.org/microarray/search/show?search_term=NPRL2)
- Allen Mouse Brain Atlas: [Gene search](https://mouse.brain-map.org/search/index.html?query=NPRL2)
- Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
- BrainSpan Developmental Transcriptome: [Developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=NPRL2)
References
GATOR1 Complex Architecture
Structure and Composition
The GATOR1 complex is a multi-subunit complex that functions as the primary negative regulator of mTORC1 signaling in response to amino acid starvation. NPRL2 forms the catalytic core of this complex[@gator]:
Each component plays distinct roles:
Rag GTPase Regulation
NPRL2 functions as a GTPase-activating protein (GAP) for Rag GTPases[@gator]:
- RagA/RagB: Rag heterodimers sense amino acid availability
- GTP hydrolysis: NPRL2 promotes Rag inactivation
- mTORC1 recruitment: Inactive Rag prevents mTORC1 lysosomal localization
- Amino acid sensing: Links nutrient status to growth signaling
Molecular Mechanisms
mTORC1 Signaling Pathway
The mTOR (mechanistic target of rapamycin) pathway is a central regulator of cell growth and metabolism[@mtor]:
Autophagy Regulation
NPRL2 indirectly regulates autophagy through mTORC1 inhibition[@autophagy]:
When NPRL2 is functional, mTORC1 remains inhibited, permitting autophagy to proceed. Loss of NPRL2 function leads to mTORC1 hyperactivation and autophagy blockade.
Brain-Specific Functions
Neuronal mTOR Regulation
In neurons, NPRL2-mediated mTOR regulation has unique features[@mechanisms]:
- Synaptic plasticity: mTOR controls local protein synthesis at synapses
- Neuronal morphology: Regulates dendritic arborization and spine formation
- Activity-dependent translation: Links neural activity to protein synthesis
- Circuit refinement: mTOR dysregulation affects circuit development
Cell Type-Specific Expression
Epilepsy Mechanisms
Focal Epilepsy
NPRL2 mutations cause autosomal dominant focal epilepsy[@nprl]:
The mechanism involves:
mTORopathies
NPRL2-related epilepsy is part of a broader group of "mTORopathies":
- Focal cortical dysplasia
- Tuberous sclerosis
- Hemimegalencephaly
- DEPDC5-related epilepsy
These disorders share mechanistic features and may respond to mTOR inhibitors.
Therapeutic Approaches
mTOR Inhibitors
Clinical considerations:
- Efficacy: Significant seizure reduction in many patients
- Adverse effects: Immunosuppression, metabolic effects
- Treatment duration: Often lifelong
- Combination therapy: May enable dose reduction
Autophagy Induction
Alternative approaches target autophagy directly[@autophagy]:
- Trehalose: mTOR-independent autophagy inducer
- Resveratrol: SIRT1-dependent autophagy
- Lithium: Autophagy through IMPase inhibition
- Carbamazepine: Autophagy enhancement
Structural Biology
Protein Domain Architecture
NPRL2 contains several functional domains:
Structural Studies
Cryo-EM studies have elucidated:
- GATOR1 complex architecture
- NPRL2-NPRL3 interaction
- Rag GTPase binding conformation
Signaling Networks
Amino Acid Sensing Pathway
Integration with Other Pathways
NPRL2 intersects with multiple signaling networks:
Clinical Implications
Diagnosis
Genetic testing for NPRL2 variants:
- Sequencing: Panel or whole exome
- Interpretation: Pathogenic vs. VUS
- Family testing: Cascade screening
Prenatal Testing
Available for:
- Known familial variants
- Preimplantation testing
- Carrier testing
Research Tools
Model Systems
Experimental Techniques
- CRISPR/Cas9 editing
- Proteomics
- Metabolomics
- Single-cell RNAseq
Therapeutic Development
Drug Targets
Clinical Trial Design
Considerations for NPRL2-related epilepsy:
- Genotype-phenotype correlation
- Seizure frequency endpoints
- Quality of life measures
- Long-term outcomes
Biomarkers
Therapeutic Response Markers
- Seizure frequency
- EEG normalization
- Cognitive function
- Brain imaging
Disease Progression
- Developmental milestones
- Neurological exam
- Biomarker levels
See Also
Pathway Diagram
The following diagram shows the key molecular relationships involving NPRL2 Gene discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-nprl2 |
| kg_node_id | NPRL2 |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-e1f3632c126d |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-nprl2'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-nprl2?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[NPRL2 Gene](http://scidex.ai/artifact/wiki-genes-nprl2)
http://scidex.ai/artifact/wiki-genes-nprl2